Worldwide Emergence of Extensively Drug-resistant Tuberculosis
Top Cited Papers
Open Access
- 1 March 2007
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 13 (3) , 380-387
- https://doi.org/10.3201/eid1303.061400
Abstract
Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR-TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000–2004. We defined extensively drug-resistant TB (XDR-TB) as MDR-TB with further resistance to ≥3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR-TB isolates, 347 (9.9%) met criteria for XDR-TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR-TB are crucial for protection of public health and control of TB.Keywords
This publication has 33 references indexed in Scilit:
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaPublished by Elsevier ,2006
- Extensively Drug‐Resistant Tuberculosis: 2 Years of Surveillance in IranClinical Infectious Diseases, 2006
- Multidrug-resistant Tuberculosis Management in Resource-limited SettingsEmerging Infectious Diseases, 2006
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosisJournal of Clinical Microbiology, 2006
- Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer AntimicrobialsJournal of Clinical Microbiology, 2006
- Increasing transparency in partnerships for health – introducing the Green Light CommitteeTropical Medicine & International Health, 2002
- Treatment of Multidrug-Resistant TuberculosisNew England Journal of Medicine, 1993
- An Outbreak of Multidrug-Resistant Tuberculosis among Hospitalized Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1992
- Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycinTubercle, 1977